Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. following a significant decline in its stock price due to disappointing performance metrics [2][4]. Group 1: Company Performance - On January 9, 2026, Beta Bionics' shares dropped approximately $11.85, or 37.04%, closing at $20.14 after the company reported preliminary fourth-quarter 2025 performance metrics that did not meet market expectations [4]. - The decline was attributed to lower-than-expected new patient starts for its iLet automated insulin delivery system, raising concerns about near-term adoption trends and revenue growth [4]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP, a prominent national securities law firm, is encouraging investors who suffered significant losses in Beta Bionics stock or options to reach out for potential claims [1][2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Helen of Troy Limited following a significant decline in the company's stock price after disappointing financial results were reported for the second quarter of fiscal 2026 [2][3][4]. Financial Performance - On October 9, 2025, Helen of Troy reported a year-over-year decline of approximately 8.9% in consolidated net sales, totaling around $431.8 million [3]. - The company reported a GAAP diluted loss per share of $13.44, influenced by significant charges, while adjusted diluted earnings per share were approximately $0.59, a substantial decrease from $1.21 in the prior-year period [3]. Stock Market Reaction - Following the financial results announcement, Helen of Troy's common stock experienced a sharp decline, falling by $6.90 per share, or about 25.0%, closing at $20.71 per share on October 9, 2025 [4].